SCHEMBL7759775

SCHEMBL7759775

CC(C)C(O)c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
SLC6A3 Q01959 3/20 0.48
SLC6A2 P23975 2/20 0.48
SLC6A4 P31645 2/20 0.48
KCNH2 Q12809 2/20 0.48
CYP2D6 P10635 2/20 0.48
TP53 P04637 1/20 0.47
CYP1A2 P05177 2/20 0.47
KDM4E B2RXH2 2/20 0.46
TSHR P16473 2/20 0.46
KCNA5 P22460 6/20 0.45
ALDH1A1 P00352 1/20 0.42
KCNE1 P15382 2/20 0.41
MAPT P10636 1/20 0.41
SLC10A1 Q14973 1/20 0.41
ABCB11 O95342 1/20 0.40
LMNA P02545 1/20 0.40
ESR1 P03372 1/20 0.40
ADRA2A P08913 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610049 1.00 CYP3A4 (0.48) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL31143650 1.00 CYP3A4 (0.48) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL31143607 1.00 CYP3A4 (0.48) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL30887869 0.87 CYP3A4 (0.47) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL20604265 0.87 CYP3A4 (0.47) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL5954472 0.87 CYP3A4 (0.47) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL9777431 0.86 SLC6A2 (0.54) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL5227874 0.83 KDM4E (0.50) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL4969094 0.83 KDM4E (0.50) CYP3A4SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL1193974 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
US-11130734-B2 Amino alcohol-boron-binol complex and method for preparing optically active amino alcohol derivative by using same MOLECULES & MATERIALS CO., LTD. (KR) 2021-09-28 US disclosed
US-20210206719-A1 AMINO ALCOHOL-BORON-BINOL COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE BY USING SAME MOLECULES & MATERIALS CO., LTD. (KR) 2021-07-08 US disclosed
CN-113072486-A Amino alcohol-boron-binaphthol complex and preparation method of optically active amino alcohol derivative using same 分子与物质株式会社 2021-07-06 CN disclosed
US-11014871-B2 “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2021-05-25 US disclosed
EP-3611164-A1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT Mitsui Chemicals Agro, Inc. (JP) 2020-02-19 EP disclosed
US-20190023645-A1 \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER UNIVERSITE PARIS-SUD (FR) 2019-01-24 US disclosed
EP-2951180-B1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME (US) 2018-05-02 EP disclosed
US-9540377-B2 2,6,7,8 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-10 US disclosed
US-9469608-B2 Thrombin inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
CN-1085218-C Olefin polymerization catalyst ASAHI CHEMICAL IND (JP) 2002-05-22 CN disclosed
US-6214954-B1 HOMO OR COPOLYMERIZING AN OLEFIN WITH POLYMERIZATION CATALYST COMPRISING A TRANSITION METAL COMPOUND, CYCLOPENTADIENYL RING CONTAINING LIGAND AND A CHELATING LIGAND, PRODUCES POLYMER WITH NARROW MOLECULAR WEIGHT DISTRIBUTION AND UNIFORMITY ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-04-10 US disclosed
EP-0798313-B1 OLEFIN POLYMERIZATION CATALYST ASAHI CHEMICAL IND (JP) 2001-03-21 EP disclosed
CN-1169736-A Catalyst for olefin polymerization ASAHI CHEMICAL IND (JP) 1998-01-07 CN disclosed
EP-0798313-A1 OLEFIN POLYMERIZATION CATALYST Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1997-10-01 EP disclosed
EP-0379928-A2 Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent BAYER AG (DE) 1990-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130734-B2 Amino alcohol-boron-binol complex and method for preparing optically active amino alcohol derivative by using same BCAT1, BCAT2, HBS1L CYP3A4 1769/4885SLC6A3 1166/4885SLC6A2 1343/4885
US-20190023645-A1 \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER HDAC6, HDAC1, HDAC5 CYP3A4 2866/4885SLC6A3 4626/4885SLC6A2 4425/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CYP3A4 854/4885SLC6A3 369/4885SLC6A2 553/4885
US-11014871-B2 “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer HDAC6, HDAC1, HDAC5 CYP3A4 2927/4885SLC6A3 4587/4885SLC6A2 4404/4885
US-20210206719-A1 AMINO ALCOHOL-BORON-BINOL COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE BY USING SAME BCAT1, BCAT2, HBS1L CYP3A4 1627/4885SLC6A3 1120/4885SLC6A2 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.